[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100364461":3},{"organization":4,"armGroups":7,"interventions":69,"overallOfficials":81,"centralContacts":110,"locations":116,"responsibleParty":147,"collaborators":81,"id":149,"slug":150,"hasResults":151,"nctId":152,"briefTitle":153,"officialTitle":153,"acronym":154,"eligibilityCriteria":155,"healthyVolunteers":151,"sex":156,"minAge":157,"maxAge":81,"enrollmentInfo":158,"targetDuration":81,"studyType":161,"phases":162,"briefSummary":164,"conditions":165,"keywords":81,"overallStatus":119,"whyStopped":81,"lastUpdateSubmitDate":172,"lastUpdatePostDateStruct":173,"startDateStruct":176,"completionDateStruct":178,"leadSponsor":180,"locationsCount":181},{"fullName":5,"class":6},"Institut du Cancer de Montpellier - Val d'Aurelle","OTHER",[8,13,17,22,27,32,37,41,46,51,55,60,65],{"label":9,"type":6,"description":10,"interventionNames":11},"COHORT 1 BREAST TUMOR\u002FPALBOCICLIB","Patient with a locally Advanced tumor or metastatic tumor RH+\u002FHER 2 - , treated by palbociclib\n\nBLOOD SAMPLING",[12],"Biological: Blood sampling",{"label":14,"type":6,"description":15,"interventionNames":16},"COHORT 2 BREAST TUMOR \u002F RIBOCICLIB","Patient with a locally Advanced tumor or metastatic tumor RH+\u002FHER 2 - , treated by ribociclib\n\nBLOOD SAMPLING",[12],{"label":18,"type":6,"description":19,"interventionNames":20},"COHORT 3 - LUNG CANCER","Patients with histologically proven metastatic bronchial carcinoma eligible for immunotherapy",[21],"Biological: Blood sampling C3",{"label":23,"type":6,"description":24,"interventionNames":25},"COHORT 4 - CCRm","Patient with metastatic colorectal adenocarcinoma",[26],"Biological: Blood sampling C4\u002F7\u002F10\u002F13",{"label":28,"type":6,"description":29,"interventionNames":30},"COHORT 5 - T-DXd","Patient with HER2 + metastatic breast cancer, requiring treatment with T-DXd",[31],"Biological: Blood sampling C5",{"label":33,"type":6,"description":34,"interventionNames":35},"COHORT 6 - Glioma","Patient with grade II, III or IV diffuse glioma",[36],"Biological: Blood sampling C6",{"label":38,"type":6,"description":39,"interventionNames":40},"COHORT 7 - CIRCUS 2","Patients with non-metastatic colon cancer",[26],{"label":42,"type":6,"description":43,"interventionNames":44},"COHORT 8 - CTC-AXL Breast","Patients with treatment-naive metastatic breast cancer with distant metastases",[45],"Biological: Blood sampling C8",{"label":47,"type":6,"description":48,"interventionNames":49},"COHORT 9 - ImmunoTNBC","Patients newly diagnosed with non-metastatic stage II - III early TNBC, requiring neoadjuvant treatment and previously untreated.",[50],"Biological: Blood sampling C9",{"label":52,"type":6,"description":53,"interventionNames":54},"COHORT 10 - LPS","Patients with well differentiated (WD) liposarcoma, dedifferentiated (DD) liposarcoma or sarcoma other than liposarcoma",[26],{"label":56,"type":6,"description":57,"interventionNames":58},"COHORT 11 - LUNG DRIVER","Patients with Metastatic bronchial carcinoma activating alterations in EGFR (del 19; L858R) or KRAS G12C",[59],"Biological: Blood sampling C11 + FFPE",{"label":61,"type":6,"description":62,"interventionNames":63},"COHORT 12 - LMD","Patient with breast cancer and suspected with leptomeningeal metastases",[64],"Biological: Blood sampling C12",{"label":66,"type":6,"description":67,"interventionNames":68},"COHORT 13 - RILA STAB","Patients with breast cancer requiring radiotherapy, whatever the tumor stage",[26],[70,77,82,86,90,94,98,102,106],{"type":71,"name":72,"description":73,"armGroupLabels":74,"otherNames":75},"BIOLOGICAL","Blood sampling","blood sampling time : cycle 1 day 15 and cycle 2 day 15 : one sample (6ml) by time",[9,14],[76],"Tumor sampling",{"type":71,"name":78,"description":79,"armGroupLabels":80,"otherNames":81},"Blood sampling C3","Blood samples will be collected at four key time points:\n\n* baseline (T1),\n* first scan assessment (T2),\n* second scan assessment (T3),\n* and progression (T4).",[18],null,{"type":71,"name":83,"description":84,"armGroupLabels":85,"otherNames":81},"Blood sampling C4\u002F7\u002F10\u002F13","Blood samples will be collected before any treatment",[52,66,23,38],{"type":71,"name":87,"description":88,"armGroupLabels":89,"otherNames":81},"Blood sampling C5","Blood samples will be collected at four key time points:\n\n* At the inclusion (T1)\n* Before the beginning of the treatment (cycle 1 day 1) (T2)\n* After the first cycle of T-DXd (cycle 2 day 1) (T3)\n* At progression or at the end of the follow-up (after 3 years) (T4)",[28],{"type":71,"name":91,"description":92,"armGroupLabels":93,"otherNames":81},"Blood sampling C6","Blood samples will be collected at three key time points:\n\n* At the inclusion (T1)\n* For patients starting treatment at the time of inclusion (T2):\n* Chemotherapy: 3 months after inclusion,\n* Concurrent chemoradiotherapy with Temozolomide: 4-6 weeks after completion of radiotherapy,\n* For patients starting treatment at the time of inclusion: at the time of tumor progression if occurring within one year of inclusion, or 12 months after inclusion in the absence of progression (T3).",[33],{"type":71,"name":95,"description":96,"armGroupLabels":97,"otherNames":81},"Blood sampling C8","Blood samples will be collected at five key time points:\n\n* At the inclusion\n* At follow-up visit 2 to 6, every 3 months",[42],{"type":71,"name":99,"description":100,"armGroupLabels":101,"otherNames":81},"Blood sampling C9","Blood samples will be collected at four key time points:\n\n* At the inclusion before the beginning of the treatment (Cycle 1 Day 1)\n* After the first cycle of the first chemo-immunotherapy sequence (Cycle 2 Day 1)\n* After the first cycle of the second chemotherapy sequence (Cycle 2b Day 1)\n* After the end of the whole neo-adjuvant chemo-immunotherapy protocol, before surgery",[47],{"type":71,"name":103,"description":104,"armGroupLabels":105,"otherNames":81},"Blood sampling C11 + FFPE","Blood samples will be collected at five key time points:\n\n* At the inclusion (T1)\n* At first clinical evaluation (T2): 4th week after start of treatment\n* At first scan evaluation (T3a): 8th week after start of treatment\n* At the Nth scan evaluation (T3b, c, ...)\n* At progression (T4)\n\nTumor sampling :\n\n* At the inclusion\n* At tumor progression",[56],{"type":71,"name":107,"description":108,"armGroupLabels":109,"otherNames":81},"Blood sampling C12","Blood samples will be collected at several points :\n\n* Inclusion: at the time of suspected leptomeningeal metastases, prior to any specific treatment,\n* Every 4 weeks until meningeal progression, or for a maximum of 4 months,\n* Then every 3 months beyond 4 months until meningeal progression.",[61],[111],{"name":112,"role":113,"phone":114,"phoneExt":81,"email":115},"texier emmannuelle","CONTACT","0467613102","emmanuelle.texier@icm.unicancer.fr",[117,139],{"facility":118,"status":119,"city":120,"state":81,"zip":121,"country":122,"countryCode":123,"cosmosGeoPoint":124,"geoPoint":129,"contacts":130},"Centre Regional de Lutte Contre le Cancer - Centre Val d'Aurelle","RECRUITING","Montpellier","34298","France","FR",{"type":125,"coordinates":126},"Point",[127,128],3.87635,43.61093,{"lat":128,"lon":127},[131,135],{"name":132,"role":113,"phone":133,"phoneExt":81,"email":134},"Marc Ychou, MD, PhD","33-4-6761-3066","mychou@valdorel.fnclcc.fr",{"name":136,"role":113,"phone":114,"phoneExt":137,"email":138},"Aurore MOUSSION","+33","aurore.moussion@icm.unicancer.fr",{"facility":140,"status":119,"city":120,"state":81,"zip":121,"country":122,"countryCode":123,"cosmosGeoPoint":141,"geoPoint":143,"contacts":144},"ICM",{"type":125,"coordinates":142},[127,128],{"lat":128,"lon":127},[145],{"name":146,"role":113,"phone":81,"phoneExt":81,"email":81},"WILLIAM JACOT",{"type":148,"investigatorFullName":81,"investigatorTitle":81,"investigatorAffiliation":81,"oldNameTitle":81,"oldOrganization":81},"SPONSOR","100364461","analysis-of-circulating-tumor-markers-in-blood-100364461",false,"NCT04025541","Analysis of Circulating Tumor Markers in Blood","ALCINA2","Inclusion Criteria:\n\n1. Patient presenting an invasive tumoral pathology (proved or suspected), whatever is the location or the stage,\n2. Man or woman ≥ 18 years,\n3. Obtaining of the informed consent signed before any procedure of specific preselection on approval.\n\nExclusion Criteria:\n\n1. Private persons of freedom or under guardianship,\n2. Patient whose regular follow-up is impossible for psychological, family, social or geographical reasons,\n3. Pregnant woman and\u002For breast-feeding,\n4. Unaffiliated patient to Social Protection System,","ALL","18 Years",{"count":159,"type":160},992,"ESTIMATED","INTERVENTIONAL",[163],"NA","The circulating tumoral biomarkers in the blood are the object of numerous researches for several decades. The potential clinical interests of these circulating biomarkers are diagnostic, prognostic, predictive of the efficiency of targeted therapies (according to the mutational profile of the cancer), and could allow the study of the mechanisms of resistance under process. In the multiplicity of these blood potential biomarkers joins a permanent evolution of the technological means used to detect them\u002Fto quantify, as well as to estimate their clinical utility.",[166,167,168,169,170,171],"Cancer","Breast Cancer","Sarcoma","Lung Cancers","Glioma","Colon Cancer","2025-03-27",{"date":174,"type":175},"2025-04-02","ACTUAL",{"date":177,"type":175},"2018-05-29",{"date":179,"type":160},"2029-05-29",{"name":5,"class":6},2]